Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
Amjevita Biosimilar Version Of Adalimumab Has Six Months With The Market To Itself
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.
